BCLI רווחיות מכירות לפי רווח נקי Brainstorm Cell Therapeutics Inc.

Geopolitical instability is complicating reagent logistics and the protection of Brainstorm Cell (BCLI) patents abroad. Operating net profit margins visualize these challenges, with the latest parameter standing at 0.00. There is a serious threat of bankruptcy due to a liquidity shortage and potential regulatory rejections for ALS therapy. However, the market value already prices in R&D risks, awaiting long-term FDA approvals for the drug NurOwn.
פילוחי מדדים פיננסיים ומדדי שוק עבור BrainStorm Cell Therapeutics Inc. (BCLI)

Net profitability reflects the share of profit remaining after deducting all operating and financial expenses. This metric measures the efficiency of converting revenue into bottom-line income. By analyzing the net profit margin, an investor assesses the business's resilience to rising costs. For Brainstorm Cell (BCLI), the volatility of this metric is driven by R&D expenditures. Geopolitical barriers and the logistics gap in cell therapy are currently exerting critical pressure on the company's final profitability.